Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes

Jayoung Lim, In-Chang Hwang, Hong-Mi Choi, Yeonyee E. Yoon, Goo-Yeong Cho
doi: https://doi.org/10.1101/2022.05.23.22275457

Article usage

Article usage: May 2022 to December 2024

AbstractFullPdf
May 2022196842
Jun 2022224656
Jul 202289652
Aug 2022791643
Sep 2022611768
Oct 2022743269
Nov 2022468074
Dec 2022464867
Jan 2023273634
Feb 2023332045
Mar 2023462762
Apr 2023592939
May 2023353122
Jun 2023268522
Jul 2023295330
Aug 2023335729
Sep 2023294945
Oct 2023182854
Nov 2023375832
Dec 2023211221
Jan 2024151928
Feb 2024483016
Mar 2024182346
Apr 202483028
May 2024211950
Jun 2024331954
Jul 2024471774
Aug 2024161451
Sep 202440761
Oct 2024281056
Nov 2024281751
Dec 2024161249
Back to top
Posted May 25, 2022.
Download PDF
Data/Code
Email
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes
Jayoung Lim, In-Chang Hwang, Hong-Mi Choi, Yeonyee E. Yoon, Goo-Yeong Cho
medRxiv 2022.05.23.22275457; doi: https://doi.org/10.1101/2022.05.23.22275457
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area